Fasoracetam is the newest member of the racetam family of nootropics that is currently being developed as a potential non-stimulant ADHD treatment.
In 2015, fasoracetam was accepted by the US Food and Drug Administration’s Investigational New Drug program, which grants the developers permission to start human clinical trials and ship the drug across state lines.
Publicly-available human studies on fasoracetam are limited but positive, indicating it may effectively treat a specific form of childhood ADHD. Animal studies and anecdotal evidence from users suggest that it may also enhance memory, improve sleep, relieve anxiety and depression, and alleviate the symptoms of withdrawal from other drugs.
Fasoracetam was created in the 1990s by the Japanese pharmaceutical company Nippon Shinyaku as a possible treatment for vascular dementia. Development was halted after disappointing clinical trials, but in 2013 the clinical data on fasoracetam (sometimes referred to in research literature as NS-105 or NFC-1) was purchased by the US-based firm NeuroFix, a subsidiary of Aevi Genomic Medicine.
Clinical trials on fasoracetam started again in 2016, investigating the compound’s potential for treating Attention Deficit Hyperactivity Disorder (ADHD) in children who demonstrate a specific mutation of the glutamate receptor system. The trials suggested that fasoracetam has potential as a non-stimulant alternative to Adderall and other amphetamine derivatives for ADHD treatment.
A phase II proof-of-concept trial was planned for 2018 to investigate fasoracetam as an autism spectrum disorder (ASD) treatment.
Fasoracetam has not been officially approved for any use by the USFDA and is classified as a research chemical that is not intended for human use.
Packaging & Shipping
1)Delivery time:within 3 days after got the order
Package Details:aluminum foil bag/dram/on request
1.A novel R&D center with advanced ventilation equipments and modern experiment equipments.
2.Two Large production factories with high capacity and meet the requirements of GMP.
3.Supplying the products from our manufacturers;
4.Custom synthesis of new products;
5.Help sourcing products and suppliers in China;
6.Assist the export and related affairs.
7.Stable quality,professional production & technology;
8.The most competitive price;
9.Steady supply, rapid delivery;
10.Perfect service, honest cooperation.
Wuhan HengHeDa Pharm Co., Ltd is a hi-tech enterprise locates in Wuhan Private Science and Technology Park, specializing in custom synthesis, manufacture and import & export of fine chemicals, APIs and pharmaceutical intermediates. HengHeDa Pharm has complete administration management and a good work team, which makes it growing fast in chemicals and pharmaceutical industry.
HengHeDa Pharm has a novel R&D center with advancedventilationequipments and modernexperimentequipments; we offer friendly working environment, have skilled people with rich experience in various kinds of experiments and talent chemists professional in R&D and QC. All of this makes us provide good quality products with high rating.
HengHeDa Pharm follows the principle of “quality first, customer above and credit fundamentality”, wishing to offer the best products to our customers.
For more detail information, please feel free to contact me.